RxDoctor Payments DataLook up a doctor →

David Almeida, MD

Ophthalmology · Erie, PANPI 1437590718

Payments from drug & device makers

$6,348,513in general payments, 2019–2025

Across 1,336 payments — averaging $4751.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche TCRC, Inc.$1.2M
  • Novartis$927K
  • Genentech, Inc.$872K
  • Ocular Therapeutix, Inc.$670K
  • Janssen Research & Development, LLC$523K
  • Boehringer Ingelheim$339K
  • plus $1.8M from 31 others
$101,239in research payments, 2019–2025

Across 8 payments — averaging $12,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eyepoint US, Inc.$66K
  • Alimera Sciences, Inc.$24K
  • Ocular Therapeutix, Inc.$11K

What the payments were for

  • Consulting fees$192,82226%
  • Speaking & faculty fees$445,76161%
  • Travel & lodging$82,48511%
  • Food & beverage$13,4042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,348,513 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,871
Medicare patients
238
Services billed
1,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate41$2,055
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$237
Latanoprost19$129
Brimonidine Tartrate15$101

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →